

Anti-SARS-CoV-2 (B.1.1.7) Neutralizing Antibody Titer Serologic Assay Kit (Spike RBD)

Pack Size: 96 tests

Catalog Number: RAS-N028

IMPORTANT: Please carefully read this manual before performing your experiment.

For Research Use Only. Not for Use in Diagnostic and Therapeutic Applications

N028-EN.02

ACCO*

INTENDED USE

This kit is developed for qualitative detection or titer measurement of Anti-SARS-CoV-2 (B.1.1.7) neutralizing antibody

(Spike RBD) in human serum. It is intended for research use only (RUO).

PRINCIPLE OF THE ASSAY

This kit is developed for detecting neutralizing antibody against SARS-CoV-2 Spike RBD with N501Y mutation in the

sample through a competitive ELISA. The microplate in the kit is pre-coated with Human ACE2 protein. To initiate the

experiment, serum samples, Positive control and Negative Control are added to the wells followed by addition of HRP-

SARS-CoV-2 Spike RBD (N501Y). After incubation, the wells are washed and Substrate Solution is added to the

wells. The reaction is terminated by the addition of Stop Solution and the intensity of absorbance is measured at 450

nm. The neutralizing antibodies in the samples will compete with ACE2 for HRP-SARS-CoV-2 Spike RBD binding. The

intensity of assay signal decrease proportionally with the concentration of Anti-SARS-CoV-2 neutralizing antibodies.

US and Canada:

Tel: +1 800-810-0816

Web: http://www.acrobiosystems.com

Asia and Pacific:

Tel: +86 400-682-2521

E-mail: order@acrobiosystems.com



MATERIALS PROVIDED

TABLE 1. MATERIALS PROVIDED

Catalog	Components	Amount (96 tests)	Format	Storage	
				Unopened	Opened
RAS028-C01	Pre-coated Human ACE2 Microplate	1 plate	Solid	2-8°C	2-8°C
RAS028-C02	Positive Control	100 μL	Liquid	2-8°C	2-8°C
RAS028-C03	Negative Control	100 μL	Liquid	2-8°C	2-8°C
RAS028-C04	HRP-SARS-CoV-2 Spike RBD (B.1.1.7)	15 μg	Powder	2-8°C, avoid light	-70°C, avoid light
RAS028-C05	10xWashing Buffer	50 mL	Liquid	2-8°C	2-8°C
RAS028-C06	Dilution Buffer	50 mL	Liquid	2-8°C	2-8°C
RAS028-C07	Substrate Solution	12 mL	Liquid	2-8°C, avoid light	2-8°C, avoid light
RAS028-C08	Stop Solution	7 mL	Liquid	2-8°C	2-8°C

REAGENTS/EOUIPMENT NEEDED BUT NOT SUPPLIED

Single or dual wavelength microplate reader with 450 nm filter;

Centrifuge;

37 °C Incubator;

Single channel or multichannel pipettes with 10 μ L, 200 μ L and 1000 μ L precision;

 $10~\mu L,\,200~\mu L$ and $1000~\mu L$ pipette tips;

Test Tubes:

Graduated cylinder;

Deionized or distilled water for dilution;

SPECIMEN COLLECTION AND STORAGE

Use a vacutainer blood collection tube to collect human serum and allow the sample to settle for at least 30 min at room temperature. Then centrifuge for 5 min at 3000 g and use the supernatant for the assay. Run the assay immediately, otherwise store the aliquot below -20°C. Avoid repeated freeze-thaw cycles.

Note:

a. Hemolysis affects the final detection result, so hemolytic samples are not suitable for this test.

US and Canada: Tel: +1 800-810-0816 Web: http://www.acrobiosystems.com



b. No detection method has been established for human plasma or whole blood samples. It is recommended that users establish their own test methods according to their needs.

STORAGE

The unopened kit is stable for 12 months from the date of manufacture if stored at 2°C to 8°C.

The opened kit should be stored per TABLE 1. The shelf life is 30 days from the date of opening.

Note:

- a. Do not use reagents past their expiration date.
- b. Find the expiration date on the outside packaging.

EAGENT PREPARATION

- 1. Bring all reagents and samples to room temperature (20°C-25°C) before use.
- 2. As recommended in Table 2, the lyophilized materials of HRP-SARS-COV-2 Spike RBD (B.1.1.7) will be diluted into a rehydrated solution with ultrapure water/deionized water. Before use, the rehydrated solution needs to be balanced at room temperature of 30 min, shake gently every 10 min. Do not shake or vortex violently. The rehydrated solution should be stored at -70°C, Do not thaw and freeze more than 3 times.

TABLE 2. RECONSTITUTION METHODS FOR 96 TESTS

Catalog	Components	Amount	Stock Solution Con.	Reconstitution Buffer and Vol.
RAS028-C04	HRP-SARS-CoV-2 Spike RBD(B.1.1.7)	15 μg	100 μg/mL	150 μL

RECOMMENDED SAMPLE PREPARATION

1. Working fluid preparation

1.1 Preparation of 1×Washing Buffer:

Dilute 50 mL 10×Washing Buffer with ultrapure water/deionized water to 500 mL.

1.2 Preparation of HRP-SARS-CoV-2 Spike RBD(B.1.1.7) working fluid:

Dilute HRP-SARS-CoV-2 Spike RBD(B.1.1.7) rehydrated solution to 0.2 µg/ml with Dilution Buffer. The prepared working fluid should avoid light. Please prepare it for one-time use only.

1.3 Preparation of Positive Control and Negative Control working fluid and pre-treatment of samples:



a. For qualitative detection of antibodies:

Dilute the samples, Positive Control and Negative Control at 1:10 with Dilution Buffer.

b. For determination of antibody titer:

It is recommended to dilute the samples, Positive Control and Negative Control from 1:10-1:320 with Dilution Buffer.

2. Plate set up

Number the diluted samples corresponding to the wells of the Pre-coated Human ACE2 Microplate. Each experiment requires a set of Positive Control and Negative Control working fluid.

3. Add samples

Add 50 μ L diluted sample, Positive Control and Negative Control working fluid to the corresponding wells, then add 50 μ L HRP-SARS-CoV-2 Spike RBD(B.1.1.7) working fluid to each well. Shake gently to mix.

Note: This step needs to be operated continuously without a long interval to not to affect the results.

4. Incubation

Incubate the plate for 1.0 h at 37°C, Avoid light.

5. Washing

Remove the solution from the wells by aspiration. Add 300 μ L 1 x Washing Buffer to each well, gently shake the plate for 30 s. Remove any remaining Washing Buffer by aspirating or decanting. Invert the plate and blot it against paper towels. Repeat the steps above for three times.

6. Substrate Reaction

Add 100 μL Substrate Solution to each well. Seal the plate with microplate sealing film and incubate at 37°C for 20 min. Avoid light.

7. Termination

Add 50 µL **Stop Solution** to each well, shake gently to mix.

Note: the color in the wells should change from blue to yellow.

8. Data Recording

Read the absorbance at 450 nm using UV/Vis microplate spectrophotometer.

US and Canada: Tel: +1 800-810-0816 Web: http://www.acrobiosystems.com



Note: To reduce the background noise, subtract the value read at $OD_{450 \, nm}$ with the value read at $OD_{630 \, nm}$.

CUT-OFF VALUE IDENTIFICATION

1. Cut-off value =20% signal inhibition.

Percent inhibition= (1 –
$$\frac{OD_{450\,\text{nm}}\ \text{of sample}}{OD_{450\,\text{nm}}\ \text{of negative control}}$$
) \times 100%

Note: The cut-off value can be determined by the end user.

- 2. Normal range of Negative control: Negative Control working fluid $OD_{450 \text{ nm}} > 0.8$
- 3. Normal range of Positive control: 1: 10 diluted Positive Control working fluid $OD_{450 \text{ nm}} < 0.1$

INTERPRETION OF RESULTS

a. For qualitative detection of antibodies:

Positive reading: Percent inhibition of sample \geq Cut-off value means Anti-SARS-CoV-2 (B.1.1.7) neutralizing antibody (Spike RBD) are detected.

Negative reading: Percent inhibition of sample <Cut-off value means Anti-SARS-CoV-2 (B.1.1.7) neutralizing antibody (Spike RBD) are not detected.

b. For determination of antibody titer:

Determination of antibody titer: the positive sample was diluted with a gradient, and the antibody titer of the sample corresponds to the highest dilution factor that still yields a positive reading.

LIMITATIONS OF THE PROCEDURE

This test is designed for detecting human serum of Anti-SARS-CoV-2 (B.1.1.7) neutralizing antibody (Spike RBD). However, we do not have the LoQ (Limit of Quantitation) and ULMI (upper limit of measuring interval) and cutoff defined for semi-quantitative detection. Interested customer is recommended to establish the semi-quantitative detection procedure themselves.

US and Canada: **Tel**: +1 800-810-0816

Tel: +86 400-682-2521

E-mail: order@acrobiosystems.com

Web: http://www.acrobiosystems.com

6/8



PERFORMANCE

Precision: Intra batch CV%<15%, Inter batch CV%<15%.

Specificity: 97.2% (two samples show false positive,n=72)

PRECAUSIONS

- 1. This kit is for research use only and is not for use in diagnostic or therapeutic applications.
- 2. This kit should be used according to the provided instructions.
- 3. Do not mix reagents from different lots.
- 4. Bring all reagents and samples to room temperature (20°C-25°C) before use. If crystals have formed in the buffer solution, incubate until the crystals have completely dissolved. Before use, bring the solution back to room temperature.
- 5. This kit should be stored at 2°C -8°C.
- 6. Please prepare the working solution of each component according to the needs of the experiment. Except for 1×Washing Buffer, all prepared working solution is for one-time use and cannot be stored.

US and Canada: Tel: +1 800-810-0816 Web: http://www.acrobiosystems.com



TYPICAL DATA

a. For qualitative detection of antibodies:

Value Result in Units	Result	Test Result Interpretation	
Sample Percent Inhibition=15%	Negative	Anti-SARS-CoV-2 (B.1.1.7) neutralizing antibody (Spike RBD) are not detected. No additional test is required.	
Sample Percent Inhibition=30%	Positive	Anti-SARS-CoV-2 (B.1.1.7) neutralizing antibody (Spike RBD) are detected. No additional test is required.	

b. For determination of antibody titer:

Note: It is recommended to optimize the dilution ratio of samples to be tested in the experiment. If you want to use a recombinant antibody for quality control, please contact us.

Ratio of Dilution	Ratio of Dilution OD _{450 nm} (Samples)		Result
10	0.572	63%	
20	0.959	37%	
40	1.011	34%	
80	1.173	23%	The titer level of antibody is 80
160	1.368	10%	antibody is 60
320	1.423	7%	
blank	1.528	0%	

US and Canada: Tel: +1 800-810-0816 Web: http://www.acrobiosystems.com